可否使用新型诊断性混合物对甲基氯异噻唑啉酮/甲基异噻唑啉酮进行斑贴试验优化？——瑞典接触性皮炎研究组的一项多中心研究。

Can patch testing with methylchloroisothiazolinone/methylisothiazolinone be optimized using a new diagnostic mix? - A multicenter study from the Swedish Contact Dermatitis Research Group.

机构信息

Department of Occupational and Environmental Dermatology, Skåne University Hospital, Lund University, Malmö, Sweden.

Department of Dermatology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.

出版信息

Contact Dermatitis. 2020 May;82(5):283-289. doi: 10.1111/cod.13483. Epub 2020 Mar 20.

DOI:10.1111/cod.13483

PMID:32112437

Abstract

BACKGROUND

Methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) and methylisothiazolinone (MI) are tested to detect contact allergy to these isothiazolinones.

OBJECTIVES

To study if an aqueous patch test preparation with MCI and MI in a mix of 0.015% and 0.2%, respectively, detects more contact allergies than the commonly used preparations of MCI/MI in 0.02% aq. and MI in 0.2% aq.

METHODS

A total of 1555 patients with dermatitis in five Swedish dermatology departments were tested consecutively with MCI/MI 0.215% aq., MCI/MI 0.02% aq., and MI 0.2% aq.

RESULTS

The share of contact allergy to MCI/MI 0.215% aq., MCI/MI 0.02% aq., and MI 0.2% aq. varied in the test centers between 7.9% and 25.9%, 3.2% and 10.3%, and 5.8% and 12.3%, respectively. MCI/MI 0.215% aq. detected significantly more patch-test positive individuals than both MCI/MI 0.02% aq. (P < .001) and MI 0.2% aq. (P < .001), as well as either one of MCI/MI and MI (P < .001). In the patients only reacting to MCI/MI 0.215% aq., 57.7% were recorded as having a dermatitis that was explained or aggravated by exposure to either MCI/MI or MI.

CONCLUSION

The results speak in favor of replacing the preparations MCI/MI 0.02% aq. and MI 0.2% aq. with MCI/MI 0.215% aq. as the screening substance in the Swedish baseline series, which has been implemented in 2020.

摘要

背景

甲基氯异噻唑啉酮/甲基异噻唑啉酮（MCI/MI）和甲基异噻唑啉酮（MI）用于检测对这些异噻唑啉酮的接触过敏。

目的

研究在 0.015%和 0.2%的混合液中分别使用 MCI 和 MI 的水性贴剂试验制剂是否比常用的 0.02% MCI/MI 和 0.2% MI 制剂检测到更多的接触过敏。

方法

在瑞典的五个皮肤科部门，对 1555 名患有皮炎的患者进行了连续测试，使用了 MCI/MI 0.215% aq、MCI/MI 0.02% aq 和 MI 0.2% aq。

结果

在测试中心，MCI/MI 0.215% aq、MCI/MI 0.02% aq 和 MI 0.2% aq 的接触过敏率在 7.9%至 25.9%、3.2%至 10.3%和 5.8%至 12.3%之间变化。MCI/MI 0.215% aq 比 MCI/MI 0.02% aq（P<.001）和 MI 0.2% aq（P<.001）以及 MCI/MI 和 MI 中的任何一种（P<.001）都能更显著地检测到贴剂阳性个体。在仅对 MCI/MI 0.215% aq 反应的患者中，57.7%的患者记录为接触 MCI/MI 或 MI 导致或加重的皮炎。